Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors

Japanese Journal of Clinical Oncology

Volumn 39, Issue 4, 2009, Pages 260-266

  Yamamoto, Noboru ^a   Yamada, Yasuhide ^a   Fujiwara, Yutaka ^a   Yamada, Kazuhiko ^a   Fujisaka, Yasuhito ^a   Shimizu, Toshio ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

MTD; Pertuzumab; Pharmacokinetics; Phase I; Solid tumors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; RO 4368451; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CANCER; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS CANCER; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERM CELL TUMOR; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOTENSION; JAPANESE; LEUKOCYTOSIS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; RASH; RECTUM CANCER; SIDE EFFECT; STOMACH CANCER; STOMATITIS; TACHYCARDIA; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DIARRHEA; DIGESTIVE SYSTEM NEOPLASMS; DRUG ERUPTIONS; FEMALE; HUMANS; HYPERSENSITIVITY; LUNG NEOPLASMS; LYMPHOPENIA; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2;

EID: 63849224412     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp006     Document Type: Article

References (26)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002;20:975-81.
3. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7.
4. Campiglio M, Ali S, Knyazev PG, Ullrich A. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J Cell Biochem 1999;73:522-32.
5. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771-7.
6. Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, et al. A potential role for activated HER-2 in prostate cancer. Semin Oncol 2000;27:76-83; discussion 92-100.
7. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
8. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
9. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003;11:495-505.
10. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
11. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
12. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717-27.
13. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28.
14. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37.
15. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550-8.
16. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003;4:120-5.
19. Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N, et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 2004;90:40-3.
20. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8.
21. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28: 1779-802.
22. Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
23. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24: 5253-8.
24. Package insert. Erbitux (Cetuximab). Branchburg, NJ: Imclone Systems and Bristol-Myers Squibb 2008.
25. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95: 1592-600.
26. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23:1275-84.